Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raptiva in moderate to severe plaque psoriasis with scalp involvement
NCT00669214Phase 4Completed
- Sponsor
- Genentech
- Start
- Feb 2008
- Primary completion
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 4, randomised, double-blind trial of efalizumab in plaque psoriasis, sponsored by Genentech. Primary endpoint: Psoriasis Scalp Severity Index 75 at 12 weeks. Started Feb 2008; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00669214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669214.